Children’s Hospital of The King’s Daughters (CHKD) is the only facility of its kind in Virginia. It was established as an 88-bed, not-for-profit hospital in 1961 by The King’s Daughters, a women’s service organization dedicated to the health and wellbeing of the community’s indigent children. Since then, CHKD has evolved into a 206-bed teaching hospital that is the clinical home of the Eastern Virginia Medical School department of pediatrics and its pediatric residency training program. CHKD is the home of the pioneering Nuss Procedure for the surgical correction of pectus excavatum and a worldwide research center for pediatric chest wall deformities. CHKD is also the heart of an extensive pediatric healthcare system that provides comprehensive medical care to children at the hospital and multi-service health centers throughout southeastern Virginia. CHKD Health System services include everything from primary care, wellness and prevention initiatives to acute inpatient care to ongoing care for chronic conditions. For more information, go to
Eriko Life Science Ventures, LLC, was founded in 2017 by 83 pediatric physicians across 24 subspecialties to accelerate the development of the PIC1 platform of molecules into pharmaceutical agents to treat pediatric and adult diseases. Eriko is a founding investor in ReAlta Life Sciences, Inc. and its physicians actively collaborate with the company providing clinical and scientific guidance.
EVMS was founded by the community in 1973 to improve health though education, research and patient care. The collaborative culture of EVMS attracts like-minded students and faculty from all over the country, encourages a multidisciplinary approach to health care and emphasizes translational research. In just 45 years, the school has grown from 24 students to an economic footprint exceeding $1.2 billion annually in southeastern Virginia. Our vision is to be recognized as the most community-oriented school of medicine and health professions in the United States. Learn more at

Strategic Partners

RRD International is a product development company that provides integrated, expert-level strategic, regulatory, and operational support to biopharmaceutical companies and investors. The Company's unique Product Development Team model (PDT) provides an effective, asset-centric alternative to traditional industry practices. While comprehensive in value, structure, and function – encompassing all aspects of a development program including strategic planning, management, and execution – the PDT model is also highly resource efficient with an intense focus on minimizing cost, time, and risk to achieve human proof-of-concept (POC). Since 2002, RRD has worked with more than 100 organizations across all major classes and therapeutic areas. For more information, visit

The PolyPeptide Group is a leading provider of custom/generic peptides for research and pharmaceutical applications. The Group has six GMP facilities worldwide. Its world-class chemists and support personnel offer an unparalleled range of services for clients of every size and at every stage of product development.